First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2025-03-07
- Target Recruit Count
- 22
- Registration Number
- NCT04882917
- Locations
- 🇺🇸
MD Anderson Center, Houston, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2023-08-15
- Target Recruit Count
- 76
- Registration Number
- NCT04768296
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸FirstHealth of the Carolinas, Inc., Pinehurst, North Carolina, United States
🇺🇸Summa Health, Akron, Ohio, United States
The MS-LINK™ Outcomes Study
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-08-22
- Target Recruit Count
- 2182
- Registration Number
- NCT04735406
- Locations
- 🇺🇸
The Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
🇺🇸Alabama Neurology Associates, Birmingham, Alabama, United States
🇺🇸Atlanta Neuroscience Institute, Atlanta, Georgia, United States
M1231 in Participants With Solid Tumors
- Conditions
- Metastatic Solid TumorsNon-Small Cell Lung CancerEsophageal Cancer
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2023-07-07
- Target Recruit Count
- 23
- Registration Number
- NCT04695847
- Locations
- 🇺🇸
MD Anderson Cancer Center - Clinical Cancer Prevention, Houston, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Study of M4344 in Combination With Niraparib
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 25
- Registration Number
- NCT04551950
- Locations
- 🇺🇸
Stanford Health Care Hospital & Clinics, Stanford, California, United States
🇪🇸Hospital Clinic i Provincial de Barcelona - Servicio de Oncologia, Barcelona, Spain
🇯🇵Osaka International Cancer Institute, Osaka-shi, Japan
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2022-12-22
- Target Recruit Count
- 3
- Registration Number
- NCT04515394
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA), Santa Monica, California, United States
🇺🇸Allegheny-Singer Research Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 11
- Registration Number
- NCT04489940
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇺🇸Medical Oncology Hematology Consultants, PA, Helen F. Graham Cancer Center, Suite 3400, Newark, Delaware, United States
🇺🇸Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Radiation: Intensity Modulation Radiation Therapy (IMRT)Drug: Placebo
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 730
- Registration Number
- NCT04459715
- Locations
- 🇺🇸
Inventa Center for Cancer Research At Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇦Medical center of Yuriy Spizhenko, Soborna Vulytsia, Kyiv, Ukraine
First in Human Study of M6223
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2023-12-08
- Target Recruit Count
- 58
- Registration Number
- NCT04457778
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada